Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 3/20 | 0.63 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CES2 | O00748 | 4/20 | 0.48 |
| ▸ | CES1 | P23141 | 4/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.44 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL9315609 | 1.00 | SLC22A1 (0.63) | SLC22A1SLC22A2ALDH1A1TSHRTP53 | |
| Tetrabuthylammonium SCHEMBL9315602 | 0.97 | SLC22A1 (0.60) | SLC22A1SLC22A2ALDH1A1TSHRTP53 | |
| Bicarbonate SCHEMBL29201411 | 0.95 | SLC22A1 (0.62) | SLC22A1SLC22A2ALDH1A1TSHRTP53 | |
| Tetrabuthylammonium SCHEMBL16093912 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2ALDH1A1TSHRTP53 | |
| Tetrabuthylammonium SCHEMBL5786104 | 0.95 | SLC22A1 (0.57) | SLC22A1SLC22A2ALDH1A1TSHRTP53 | |
| Tetrapentylammonium SCHEMBL2274108 | 0.95 | SLC22A1 (0.63) | SLC22A1SLC22A2ALDH1A1TSHRTP53 | |
| Tetrahexylammonium SCHEMBL2275860 | 0.92 | SLC22A1 (0.65) | SLC22A1SLC22A2ALDH1A1TSHRTP53 | |
| Bicarbonate SCHEMBL20984991 | 0.92 | SLC22A1 (0.65) | SLC22A1SLC22A2ALDH1A1TSHRTP53 | |
| Tetrabuthylammonium SCHEMBL106861 | 0.92 | SLC22A1 (0.67) | SLC22A1SLC22A2ALDH1A1TSHRTP53 | |
| Bicarbonate SCHEMBL8856951 | 0.91 | SLC22A1 (0.52) | SLC22A1SLC22A2ALDH1A1TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1064 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12615983-B2 | Methods for wet atomic layer etching of silicon dioxide | TOKYO ELECTRON LIMITED (JP) | 2026-04-28 | — | — | US | claimed |
| US-20250293039-A1 | METHODS FOR WET ATOMIC LAYER ETCHING OF SILICON DIOXIDE | TOKYO ELECTRON LIMITED (JP) | 2025-09-18 | — | — | US | claimed |
| US-20250162993-A1 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | THE JOHNS HOPKINS UNIVERSITY | 2025-05-22 | — | — | US | claimed |
| WO-2025080839-A1 | IMPROVED RADIOSYNTHESIS OF 18F-LABELED NUCLEOSIDE ANALOGUES | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2025-04-17 | — | — | WO | claimed |
| CN-119080714-A | Azobenzenesulfonate compound, preparation method and application thereof, and preparation method of radioactive probe | 四川大学 | 2024-12-06 | — | — | CN | claimed |
| EP-3481804-B1 | IMPROVED SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPyL | UNIV JOHNS HOPKINS (US) | 2024-11-27 | — | — | EP | claimed |
| CN-117603117-B | Preparation method of chiral 3- (2-haloacetyl) -4-ethylpyrrolidine | 江苏海洋大学 | 2024-10-29 | — | — | CN | claimed |
| CN-118792710-A | Metal aluminum electrode modified by functional nano interface layer and preparation method thereof | 中南大学 | 2024-10-18 | — | — | CN | claimed |
| CN-118771310-A | No-drying18F-Solution, preparation method and application thereof | 四川大学华西医院 | 2024-10-15 | — | — | CN | claimed |
| CN-118561313-A | Method for synthesizing copper halide-based colloid nanocrystalline at room temperature and application | 浙江大学 | 2024-08-30 | — | — | CN | claimed |
| EP-1392650-B1 | PROTECTED TYROSINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND USE OF THE SAME FOR PRODUCING O-(2- ?18 F]-FLUOROETHYL)-L-TYROSINE | FORSCHUNGSZENTRUM JUELICH GMBH (DE) | 2005-03-02 | — | — | EP | claimed |
| US-20040265232-A1 | [18F]-furanosylpurine derivatives and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-12-30 | — | — | US | claimed |
| WO-2004096138-A2 | [18F]-FURANOSYLPURINE DERIVATIVES AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2004-11-11 | — | — | WO | claimed |
| US-20040192954-A1 | Protected tyrosine derivatives, method for the production thereof and use of the same for producing o-(2-[18f]-fluoroethyl)-l-tyrosine | FORSCHUNGSZENTRUM GMBH (DE) | 2004-09-30 | — | — | US | claimed |
| EP-1142049-B1 | HYDROFLUORIC ACID SCAVENGER | DANIONICS AS (DK) | 2002-09-18 | — | — | EP | claimed |
| WO-2000042672-A9 | HYDROFLUORIC ACID SCAVENGER | DANIONICS AS (DK) | 2001-11-15 | — | — | WO | claimed |
| EP-1142049-A2 | HYDROFLUORIC ACID SCAVENGER | DANIONICS A/S (DK) | 2001-10-10 | — | — | EP | claimed |
| WO-2000042672-A2 | HYDROFLUORIC ACID SCAVENGER | DANIONICS A/S (DK) | 2000-07-20 | — | — | WO | claimed |
| US-5693599-A | Flux washing agent | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1997-12-02 | — | — | US | claimed |
| US-5169942-A | Using a quaternary phase-transfer agent, deacylation, fluorination | GENERAL ELECTRIC COMPANY (US) | 1992-12-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12615983-B2 | Methods for wet atomic layer etching of silicon dioxide | SIGLEC7, SIGLEC9, ASH2L | SLC22A1 2411/4885SLC22A2 2139/4885ALDH1A1 2020/4885 |
| US-20040192954-A1 | Protected tyrosine derivatives, method for the production thereof and use of the same for producing o-(2-[18f]-fluoroethyl)-l-tyrosine | TH, TYR, TYRO3 | SLC22A1 2489/4885SLC22A2 3060/4885ALDH1A1 1316/4885 |
| US-20250162993-A1 | SYNTHESIS OF THE RADIOLABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) INHIBITOR [18F]DCFPYL | FOLH1, KLK3, BPHL | SLC22A1 766/4885SLC22A2 938/4885ALDH1A1 1969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.